2019 Cannabis Clinical Trials DEA 
NORML
OCTOBER 21, 2019
A federal court on Friday denied a petition for a writ of mandamus that sought to order the US Drug Enforcement Administration to begin licensing private entities that wish to cultivate cannabis. The agency in 2016 first announced its intent to license private entities to grow cannabis for FDA-approved clinical trials.
NORML
JANUARY 17, 2019
A bipartisan coalition of House lawmakers has introduced The Medical Cannabis Research Act of 2019 ( HR 601 ), to facilitate federally-approved clinical trials involving cannabis. Click here to send a message to your Representative and urge them to support the measure. .
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Cannabis Law Report
FEBRUARY 10, 2022
Court of Appeals for the Ninth Circuit dismissed a petition for review of a Drug Enforcement Administration (DEA) response to an attorney’s letter seeking advice and guidance on how a physician could administer psilocybin to a terminally ill patient without incurring liability under the Controlled Substances Act (CSA). By Allison Campbell.
Cannabis Law Report
MAY 29, 2022
In May 2019, Denver became the first city to decriminalize psilocybin, followed by Oakland, CA, Washington, D.C., In 2019, FDA approved Spravato (esketamine) nasal spray for treatment of depression in adults. [8] 8] Spravato is derived from ketamine and categorized by DEA as a Schedule III controlled substance.
Cannabis Law Report
MAY 31, 2022
The only psychedelic drug that is approved (outside of clinical trials) for psychiatric use—as opposed to anesthesia—through the traditional medical system is Ketamine. On March 5, 2019, the U.S. 2022 Active FDA Clinical Trials and State-Regulated Systems. Active FDA Regulated Clinical Trials*.
Cannabis Law Report
SEPTEMBER 20, 2019
17, 2019 /PRNewswire/ — PRESS RELEASE — GB Sciences, Inc. 13, 2019, filed an 8k announcing the sale of its 50-percent ownership stake in GB Sciences Louisiana, LLC. LAS VEGAS, Sept. on Friday, Sep.
Cannabis Law Report
JULY 9, 2021
Denver, Colorado was the first jurisdiction to decriminalize the use of psilocybin via ballot initiative in May 2019. Then, in November 2019, the FDA granted the designation to the nonprofit Usona Institute to study psilocybin’s effect on major depressive order, for which clinical trials are currently under way.
Expert insights. Personalized for you.
104 
Let's personalize your content